Scarica l'app Stockscreener
0.00
100.00%
-131.87
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
(ITCI) Long Term Investment Analysis - news.stocktradersdaily.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Cetera Investment Advisers - Defense World
Intra-Cellular Therapies describes new PDE1 inhibitors - BioWorld MedTech
Quantinno Capital Management LP Takes $256,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com - Defense World
(ITCI) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Dealmaking Quarterly Statistics, Q1 2025 - insights.citeline.com
Press Release Distribution & PR Platform - ACCESS Newswire
Trend Tracker for (ITCI) - news.stocktradersdaily.com
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery - Yahoo Finance
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal - TradingView
Johnson & Johnson Reports Q1 2025 Results - BioSpace
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock - Investing.com Canada
Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock By Investing.com - Investing.com South Africa
Johnson & Johnson - drugdiscoverytrends.com
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MSN
J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal - ROI-NJ
J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer
Johnson & Johnson buys Bedminster drugmaker for $14.6B - NJBIZ
JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues
JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com South Africa
Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks
Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga
Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace
Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener
JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq
Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com
Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks
Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider
Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize
Pharma Pulse 4/2/25: Financial Barrier to GLP-1s, The Future of Healthcare is Digital & more - PharmExec
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq
Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada
Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com
Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks
Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider
Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - The Joplin Globe
Intra-cellular Therapeutics Surges to 322nd in Trading Volume Ranking with 3.36 Billion Shares Exchanged - AInvest
(ITCI) On The My Stocks Page - news.stocktradersdaily.com
Intra-cellular Therapies Surges to 340th in Daily Rankings with 2.46 Billion Turnover - AInvest
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com
Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com
Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma
0.26%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):